Edition:
United Kingdom

Sihuan Pharmaceutical Holdings Group Ltd (0460.HK)

0460.HK on Hong Kong Stock

1.97HKD
19 Apr 2018
Change (% chg)

HK$-0.02 (-1.01%)
Prev Close
HK$1.99
Open
HK$1.98
Day's High
HK$2.04
Day's Low
HK$1.96
Volume
22,103,000
Avg. Vol
18,615,473
52-wk High
HK$3.76
52-wk Low
HK$1.92

Latest Key Developments (Source: Significant Developments)

Hainan Sihuan Pharmaceutical to invest 200 mln yuan in Pharmadax Foshan unit
Monday, 4 Sep 2017 

Sept 4 (Reuters) - Pharmadax Inc <4191.TWO> ::* Says it and units signed agreement with Hainan Sihuan Pharmaceutical Co Ltd and Sihuan Pharmaceutical Holdings Group.* Hainan Sihuan Pharmaceutical Co Ltd plans to invest initial 200 million yuan in its Foshan-based pharma unit, to buy 19.99 percent stake and corporate bonds, for equity investment and strategic cooperation.  Full Article

Sihuan Pharmaceutical Holdings says HY revenue RMB1.44 bln
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>:HY profit attributable to owners of co up by 14.5 pct to about RMB842.5 million.HY revenue RMB1.44 billion, up 3.8 pct.Interim dividend RMB1.8 cents per share.  Full Article

Sihuan Pharmaceutical Holdings announces appointment of group vice president for research and development
Monday, 31 Jul 2017 

July 31 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::Appointment of Guo Feng as group vice president (research and development).Jia Zhongxin has retired recently as chief operating officer of group.  Full Article

Sihuan Pharmaceutical Holdings announces establishment joint venture
Monday, 12 Jun 2017 

June 12 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::Croma-Pharma recently received China food and drug administration-approval for Princess Volume dermal filler.Establishes joint venture on minimally-invasive aesthetic products.‍Sales of Princess Volume dermal filler is expected to start as early as July 2017​.  Full Article

Sihuan Pharmaceutical updates on deal with Buchang Pharma regarding distributorship of two products
Tuesday, 16 May 2017 

May 16 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::Company has recently entered into an agreement with Buchang Pharma with respect to distributorship of two products."Currently, Buchang Pharma has 100% equity interests in Tonghua Guhong, and intends to terminate distributorship arrangement with group".Following disposal of 50% interest in Jilin Sichang, group intends to retrieve its nationwide distributorship of Qunao from Buchang.As per distribution deal between co & Buchang, arrangement between Tonghua Guhong and Buchang on Guhong product shall be terminated.As per distribution deal between co & Buchang, arrangement between Jilin Sihuan and buchang on Qunao Product shall also be terminated.  Full Article

Sihuan Pharmaceutical posts FY profit attributable of RMB 1.71 bln
Tuesday, 28 Mar 2017 

Sihuan Pharmaceutical Holdings Group Ltd <0460.HK> : Board recommends declaration and payment of a final cash dividend of RMB3.8 cents per share and a special cash dividend of RMB5.5 cents per share . FY revenue RMB3.19 billion, up 0.6 pct .FY profit attributable to owners of company RMB 1.71 billion versus RMB 2.06 billion.  Full Article

Sihuan Pharmaceutical says unit entered into an equity acquisition agreement with Ambest Pharmaceutical
Wednesday, 22 Mar 2017 

Sihuan Pharmaceutical Holdings Group Ltd <0460.HK> : Sun Moral International (hk) recently entered into an equity acquisition agreement with Ambest Pharmaceutical Company Limited .Agreement to acquire 100% equity interest held by transferor in ambest pharmaceutical for rmb1.1 billion.  Full Article

Sihuan Pharmaceutical Holdings Group says HY revenue RMB 1.39 billion, down 21.8 pct<0460.HK>
Tuesday, 23 Aug 2016 

Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>: Announcement of interim results for the six months ended 30 June 2016 <0460.HK> . HY profit attributable to owners of the company decreased by 49.3% to approximately RMB736.0 million . Interim dividend of RMB1.4 cents per share was declared by the board . It is expected that the government will maintain tight control over excessive growth in medical expenditure . Says HY revenue RMB 1.39 billion, down 21.8% . Lowering of provincial drug tender prices and implementation of "two-invoice system" to continue to pressure the pharmaceutical industry . Says rigid demand in the domestic pharmaceutical market will continue to grow .  Full Article